Search Results

You are looking at 71 - 80 of 199 items for :

  • "Metastatic breast cancer" x
Clear All
Full access

Rachel M. Layman

treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial . Lancet Oncol 2016 ; 17 : 425

Full access

Amelia B. Zelnak and Ruth M. O'Regan

currently under investigation. Until definitive data are available, extending therapy may be reasonable in patients with high-risk disease, particularly if they are tolerating treatment well. Metastatic Breast Cancer First-Line Therapy Before

Full access

Betsy L. Althaus

increasing dose intensity . Am J Clin Oncol 1999 ; 22 : 38 – 41 . 22. Livingston RB Ellis GK Gralow JR . Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer

Full access

Shankar Sellappan, Adele Blackler, Wei-Li Liao, Emily O'Day, Peng Xu, Sheeno Thyparambil, Fabiola Cecchi, Todd Hembrough and Daniel V.T. Catenacci

predictive biomarker of pertuzumab efficacy by interrupting HER2/HER3 signaling. 13 , 14 The CLEOPATRA study of first-line therapy for patients with HER2-positive metastatic breast cancer demonstrated significantly improved overall survival (OS) with the

Full access

Rachel F. Dear, Kevin McGeechan, Megan B. Barnet, Alexandra L. Barratt and Martin H.N. Tattersall

: RCTs, randomized controlled trials. sponsored by industry. Most trials did not use blinding. Half were in the setting of metastatic breast cancer, almost one-quarter included only HER2-positive disease, and almost one-third included only ER

Full access

0150197 10.6004/jnccn.2017.0020 Identifying Educational Needs of the Multidisciplinary Cancer Team in the Treatment of Metastatic Breast Cancer Wanchoo Priya a MD Larrison Chris b Rosenberg Carol c MD Ko Naomi c MD, MPH Cantril

Full access

Joanne Mortimer and Mary Mendelsohn

currently in the process of building electronic order sets for the electronic record. All orders for treating metastatic breast cancer include pamidronate, zoledronic acid, or denosumab. Adding orders for bone-directed therapies was recognized to be of

Full access

Apostolia M. Tsimberidou, Alexandra M. Adamopoulos, Yang Ye, Sarina Piha-Paul, Filip Janku, Siqing Fu, David Hong, Gerald S. Falchook, Aung Naing, Jennifer Wheler, Adoneca Fortier, Razelle Kurzrock and Kenneth R. Hess

cell lung cancer, and breast cancer. 2 - 9 In a study comparing bendamustine, methotrexate, and fluorouracil (n=25) with cyclophosphamide, methotrexate, and fluorouracil (n=24) 10 in patients with metastatic breast cancer, the bendamustine combination

Full access

10.6004/jnccn.2014.0182 Genomic Analysis of Breast Cancer Heralds a Changing Treatment Paradigm Ellis Matthew MB, BChir, PhD 05 2014 12 12 5S 5S 750 750 752 752 0120750 10.6004/jnccn.2014.0183 Treatment of Metastatic Breast Cancer

Full access

William T. McGivney

paclitaxel in combination be a treatment option for women with metastatic breast cancer. The vote of the NCCN Guidelines Panel on this issue was 15 to 0. The European Medicines Agency, the counterpart of the FDA for the European Union, has adopted a position